Results 1 to 10 of about 2,687 (162)

Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers

Pharmaceutics, 2022
Several gastrin-releasing peptide receptor (GRPR) antagonists with improved in vivo behavior have been recently developed and tested in the clinic. However, despite the generally mild side effects of peptide receptor radionuclide therapy (PRRT), toxicity
Alice D'Onofrio, L Gano, FRANCISCO Silva   +2 more
exaly   +5 more sources

Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cells [PDF]

EJNMMI Research
Background Gastrin releasing peptide receptor (GRPR)-targeting radiotracers have been studied (pre)-clinically with promising results. Patients eligible for this treatment are likely to have undergone prior treatments with other anti-cancer agents ...
Simone Dalm, Corrina De Ridder, Dalm Simone U   +2 more
exaly   +3 more sources

GRPR-targeting radiotheranostics for breast cancer management

Frontiers in Medicine, 2023
Breast Cancer (BC) is the most common cancer worldwide and, despite the advancements made toward early diagnosis and novel treatments, there is an urgent need to reduce its mortality.
Axel Rominger, Tilman Läppchen, Eleni Gourni   +2 more
exaly   +5 more sources

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer [PDF]

Cancers, 2019
Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) could improve the diagnostic accuracy in prostate cancer (PCa). The aim of this study was to develop a PSMA/GRPR-targeting bispecific heterodimer for SPECT and positron emission tomography (PET) diagnostic imaging of PCa.
Anna Orlova, Mats Larhed, Bogdan Mitran   +2 more
exaly   +4 more sources

The gastrin-releasing peptide receptor as a potential biomarker for squamous cell carcinoma [PDF]

Scientific Reports
The gastrin-releasing peptide receptor (GRPR) is expressed across multiple human cancer types, including head and neck tumors, and has also been detected in the oral mucosa of patients bearing head and neck neoplasms.
Danielly Brufatto Olguins, Júlia Caroline Marcolin, Mariane da Cunha Jaeger, Manoela Domingues Martins, Luis Fernando da Rosa Rivero, Gilberto Schwartsmann, Rafael Roesler, Marcelo Gerardin Poirot Land, Martina Lichtenfels, Caroline Brunetto de Farias   +9 more
doaj   +2 more sources

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer [PDF]

Pharmaceutics, 2020
The targeting of gastrin-releasing peptide receptors (GRPR) was recently proposed for targeted therapy, e.g., radiotherapy. Multiple and frequent injections of peptide-based therapeutic agents would be required due to rapid blood clearance. By conjugation of the GRPR antagonist RM26 (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) to an ABD (albumin-binding
Anna Orlova, Amélie Eriksson Karlström, Vladimir Tolmachev   +2 more
exaly   +5 more sources

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches

Frontiers in Oncology, 2023
IntroductionCentral to targeted radionuclide imaging and therapy of prostate cancer (PCa) are prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals. Gastrin-releasing peptide receptor (GRPR) targeting has been proposed as a potential additional approach for PCa theranostics. The aim of this study was to investigate to what extent and
Hayri E Balcioglu, Simone Dalm, Wytske Van Weerden   +2 more
exaly   +4 more sources

Novel insight on GRP/GRPR axis in diseases

Biomedicine and Pharmacotherapy, 2023
The gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupled receptors (GPCRs), binds to ligands such as gastrin-releasing peptide (GRP) and plays a variety of biological roles. GRP/GRPR signalling is involved in the pathophysiological processes of many diseases, including inflammatory diseases, cardiovascular diseases, neurological
Xiao-Ming Meng, Juan Jin
exaly   +3 more sources

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics [PDF]

Frontiers in Oncology
The gastrin-releasing peptide receptor (GRPR) is aberrantly expressed in several malignancies, including prostate cancer, breast cancer, lung cancer, and gastrointestinal stromal tumors, making it an important target for molecular imaging and targeted ...
YunLong Yang, YunLong Yang, Jiang Fu, ShengJie Tang, Tao Liu, HaiYang Hu, HaiYang Guo, Long Wen, Long Wen, Yang Yang, Yang Yang, ChengKuan Liu, ChengKuan Liu, GuiYan Yi, Li Yu, HaiNing Zhou, HaiNing Zhou, HaiNing Zhou, HaiNing Zhou   +18 more
doaj   +2 more sources

Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer. [PDF]

Cancer Innov
Potential biomarkers for the development of targeted radionuclide therapy that can be employed in the treatment of breast cancer have been summarised in the review. They include receptor markers of ER, PR and HER2, as well as other markers of Trop2, PD‐1, EGFR, GRPR and PSMA.
Tan Y, Zeng C, Wang J, Ma F.
europepmc   +2 more sources